Christopher Garabedian

2013

In 2013, Christopher Garabedian earned a total compensation of $9.7M as Former President and Chief Executive Officer at Sarepta Therapeutics, a 267% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$362,500
Option Awards$8,576,970
Salary$580,000
Other$182,022
Total$9,701,492

Garabedian received $8.6M in option awards, accounting for 88% of the total pay in 2013.

Garabedian also received $362.5K in non-equity incentive plan, $580K in salary and $182K in other compensation.

Rankings

In 2013, Christopher Garabedian's compensation ranked 430th out of 12,286 executives tracked by ExecPay. In other words, Garabedian earned more than 96.5% of executives.

ClassificationRankingPercentile
All
430
out of 12,286
97th
Division
Manufacturing
132
out of 4,612
97th
Major group
Chemicals And Allied Products
34
out of 1,466
98th
Industry group
Drugs
21
out of 1,160
98th
Industry
Pharmaceutical Preparations
19
out of 890
98th
Source: SEC filing on May 31, 2016.

Garabedian's colleagues

We found four more compensation records of executives who worked with Christopher Garabedian at Sarepta Therapeutics in 2013.

2013

Sandesh Mahatme

Sarepta Therapeutics

Chief Financial Officer

2013

Edward Kaye

Sarepta Therapeutics

Chief Executive Officer

2013

David Howton

Sarepta Therapeutics

General Counsel

2013

Jayant Aphale

Sarepta Therapeutics

Senior Vice President, Technical Operations

In-depth

You may also like